

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date: February 8, 2005	Attorney Docket No.	Client Ref.
	056291-5199	10/523836
	Applicant: Stephen Robert WEDGE	
	Appln. No.: To Be Assigned	
	Filing Date: Concurrently	
Examiner: Unassigned		Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
	GR							
	HR							
	IR							
	JR							
	KR							
	LR							
	MR							
	NR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

OR	Magné et al., British Journal of Cancer, vol. 86, No. 5, 4 March 2002, pp. 819-827			
PR	Ciardiello et al., Clinical Cancer Research, The American Association for Cancer Research, vol. 6, no. 5, May 2000, pp. 2053-2063			
QR	Holden et al., European Journal of Cancer, vol. 37, no. Supplement 6, October 2001, p. S73			
RR	Hennequin et al., Journal of Medicinal Chemistry, vol. 45, no. 6, 14 March 2002, pp. 1300-1312			
SR	"Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR 'KDRI-TKI), in a model of ZD1839 ('Iressa') resistance", European Journal of Cancer, vol. 38, November 2002, pp. S60-S61			
TR	Manley et al., Expert Opinion on Investigational Drugs, vol. 11, no. 2, Dec. 2002, pp. 1715-1736			
UR				
VR				

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	